Compounds > ddd107498
Page last updated: 2024-11-13

ddd107498

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

DDD107498: has antimalarial activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71748268
CHEMBL ID4091762
SCHEMBL ID15322600
MeSH IDM000607649

Synonyms (34)

Synonym
M-5717 ,
6-fluoro-2-[4-(morpholinomethyl)phenyl]-n-(2-pyrrolidin-1-ylethyl)quinoline-4-carboxamide
BENUHBSJOJMZEE-UHFFFAOYSA-N
SCHEMBL15322600
ddd107498
ddd-107498
6-fluoro-2-(4-(4-morpholinylmethyl)phenyl)-n-(2-(1-pyrrolidinyl)ethyl)-4-quinolinecarboxamide
4-quinolinecarboxamide, 6-fluoro-2-(4-(4-morpholinylmethyl)phenyl)-n-(2-(1-pyrrolidinyl)ethyl)-
e3oc1cu1f4 ,
unii-e3oc1cu1f4
NCGC00490685-01
M5717 ,
ZB1568
6-fluoro-2-(4-(morpholinomethyl)phenyl)-n-(2-(pyrrolidin-1-yl)ethyl)quinoline-4-carboxamide
BS-15456
cabamiquine [inn]
gtpl9737
6-fluoro-2-[4-(morpholin-4-ylmethyl)phenyl]-n-(2-pyrrolidin-1-ylethyl)quinoline-4-carboxamide
mmv121
cabamiquine
ddd498
EX-A3086
SB18682
1469439-69-7
BCP31981
m 5717
D81093
CHEMBL4091762
mmv-121
AKOS037515684
AC-35743
HY-117684
bdbm50550147
CS-0066858

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)		0.51
"Many lead compounds fail to reach clinical trials despite being potent because of low bioavailability attributed to their insufficient solubility making solubility a primary and crucial factor in early phase drug discovery."( Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
Baidya, ATK; Das, B; Kumar, R; Mathew, AT; Yadav, AK, 2022)		0.72
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)16.00000.00091.901410.0000AID1685971
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (22)

Processvia Protein(s)Taxonomy
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (71)

Assay IDTitleYearJournalArticle
AID1439851Selectivity index, ratio of IC50 for rat L6 cells to IC50 for erythrocytic stage of chloroquine/pyrimethamine-resistant Plasmodium falciparum K12017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
New derivatives of quinoline-4-carboxylic acid with antiplasmodial activity.
AID1714192Antimalarial activity against drug resistant Plasmodium falciparum K12016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
In Vivo and In Vitro Optimization of Screening Antimalarial Hits toward Lead Molecules for Preclinical Development.
AID1685992Volume of distribution at steady state in Sprague-Dawley rat at 1 mg/kg, iv administered as bolus dose by UPLC-MS/MS analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1685989Antiplasmodial activity against Plasmodium berghei ANKA infected in NMRI mouse assessed as survival days at 1 mg/kg, po QD for 4 days2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1685986Antiplasmodial activity against Plasmodium berghei infected in NMRI mouse assessed as reduction in parasitemia at 3 mg/kg, po QD for 4 days2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1686013Tmax in Sprague-Dawley rat at 5 mg/kg, po administered via gavage by UPLC-MS/MS analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1686004Antiplasmodial activity against drug resistant Plasmodium falciparum V1/S by [3H]hypoxanthine incorporation assay2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1686012Cmax in Sprague-Dawley rat at 5 mg/kg, po administered via gavage by UPLC-MS/MS analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1714194Antimalarial activity against drug resistant Plasmodium falciparum NF52016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
In Vivo and In Vitro Optimization of Screening Antimalarial Hits toward Lead Molecules for Preclinical Development.
AID1439849Antiplasmodial activity against erythrocytic stage of chloroquine/pyrimethamine-resistant Plasmodium falciparum K1 assessed as reduction in [3H]hypoxanthine incorporation after 48 hrs by liquid scintillation counting method2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
New derivatives of quinoline-4-carboxylic acid with antiplasmodial activity.
AID1685979Oral bioavailability in NMRI mouse at 10 mg/kg administered via gavage by UPLC-MS/MS analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1685982Antiplasmodial activity against Plasmodium berghei ANKA infected in NMRI mouse assessed as cure rate at 30 mg/kg, po QD for 4 days2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1685965Intrinsic clearance in CD1 mouse liver microsomes at 0.5 uM in presence of NADPH incubated upto 30 mins by UPLC-MS/MS analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1686011Tmax in NMRI mouse at 3 mg/kg, po administered as gavage by UPLC-MS/MS analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1686002Antiplasmodial activity against drug resistant Plasmodium falciparum TM90C2A by [3H]hypoxanthine incorporation assay2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1714197Antimalarial activity against Plasmodium yoelii2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
In Vivo and In Vitro Optimization of Screening Antimalarial Hits toward Lead Molecules for Preclinical Development.
AID1685960Antiplasmodial activity against Plasmodium berghei ookinete form assessed as growth inhibition incubated for 22 hrs by GFP-based fluorescence microscopic analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1685987Antiplasmodial activity against Plasmodium berghei ANKA infected in NMRI mouse assessed as survival days at 3 mg/kg, po QD for 4 days2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1686008Half-life in NMRI mouse at 1 mg/kg, iv administered as bolus dose by UPLC-MS/MS analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1714191Antimalarial activity against drug resistant Plasmodium falciparum TM90C2A2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
In Vivo and In Vitro Optimization of Screening Antimalarial Hits toward Lead Molecules for Preclinical Development.
AID1685998Antiplasmodial activity against GFP-transfected Plasmodium berghei ANKA infected in NMRI mouse assessed as reduction in parasitemia by measuring effective dose administered once daily oral dose for 4 days2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1686014AUC in Sprague-Dawley rat at 5 mg/kg, po administered via gavage by UPLC-MS/MS analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1439848Cytotoxicity against rat L6 cells after 70 hrs by alamar blue staining based fluorometric assay2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
New derivatives of quinoline-4-carboxylic acid with antiplasmodial activity.
AID1685964Antiproliferative activity against human MRC5 cells assessed as reduction in cell viability after 68 hrs by resazurin dye based fluorescence assay2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1685969Intrinsic clearance in human liver microsomes at 0.5 uM in presence of NADPH incubated upto 30 mins by UPLC-MS/MS analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1714189Antimalarial activity against drug resistant Plasmodium falciparum V1/S2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
In Vivo and In Vitro Optimization of Screening Antimalarial Hits toward Lead Molecules for Preclinical Development.
AID1866033Antimalarial activity against blood stage chloroquine-sensitive Plasmodium falciparum 3D7 infected in human red blood cells measured by [3H]hypoxanthine incorporation assay2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
AID1685997Oral bioavailability in Sprague-Dawley rat at 3 mg/kg administered via gavage by UPLC-MS/MS analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1685983Antiplasmodial activity against Plasmodium berghei ANKA infected in NMRI mouse assessed as reduction in parasitemia at 10 mg/kg, po QD for 4 days2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1685962Antiplasmodial activity against late stage (IV/V) Plasmodium falciparum NF54 gametocytes transfected with GFP-LUC assessed as growth inhibition incubated for 72 hrs by mitotracker Red-CMXROS dye based fluorescence microscopic analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1686010AUC in NMRI mouse at 3 mg/kg, po administered as gavage by UPLC-MS/MS analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1685966Kinetic aqueous solubility of the compound by laser nephelometry2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1685991Clearance in Sprague-Dawley rat blood at 1 mg/kg, iv administered as bolus dose by UPLC-MS/MS analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1866020Thermodynamic aqueous solubility of the compound2022Bioorganic & medicinal chemistry, 02-15, Volume: 56Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
AID1686006Blood clearance in NMRI mouse at 1 mg/kg, iv administered as bolus dose by UPLC-MS/MS analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1439847Antiplasmodial activity against erythrocytic stage of chloroquine-sensitive Plasmodium falciparum NF54 assessed as reduction in [3H]hypoxanthine incorporation after 48 hrs by liquid scintillation counting method2017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
New derivatives of quinoline-4-carboxylic acid with antiplasmodial activity.
AID1714193Antimalarial activity against drug resistant Plasmodium falciparum W22016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
In Vivo and In Vitro Optimization of Screening Antimalarial Hits toward Lead Molecules for Preclinical Development.
AID1714199Aqueous solubility of compound2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
In Vivo and In Vitro Optimization of Screening Antimalarial Hits toward Lead Molecules for Preclinical Development.
AID1714190Antimalarial activity against drug resistant Plasmodium falciparum 7G82016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
In Vivo and In Vitro Optimization of Screening Antimalarial Hits toward Lead Molecules for Preclinical Development.
AID1685959Antiplasmodial activity against drug resistant Plasmodium falciparum NF5 by [3H]hypoxanthine incorporation assay2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1686003Antiplasmodial activity against drug resistant Plasmodium falciparum D6 by [3H]hypoxanthine incorporation assay2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1685980Antiplasmodial activity against Plasmodium berghei ANKA infected in NMRI mouse assessed as reduction in parasitemia at 30 mg/kg, po QD for 4 days2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1714198Intrinsic clearance in mouse liver microsomes2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
In Vivo and In Vitro Optimization of Screening Antimalarial Hits toward Lead Molecules for Preclinical Development.
AID1686009Cmax in NMRI mouse at 3 mg/kg, po administered as gavage by UPLC-MS/MS analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1685967Permeability of the compound at 10 uM incubated for 5 hrs by UPLC-MS/MS analysis based PAMPA method2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1714188Antimalarial activity against drug resistant Plasmodium falciparum D62016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
In Vivo and In Vitro Optimization of Screening Antimalarial Hits toward Lead Molecules for Preclinical Development.
AID1685968Intrinsic clearance in Sprague-Dawley rat liver microsomes at 0.5 uM in presence of NADPH incubated upto 30 mins by UPLC-MS/MS analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1686007Volume of distribution at steady state in NMRI mouse at 1 mg/kg, iv administered as bolus dose by UPLC-MS/MS analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1685957Antiplasmodial activity against drug resistant Plasmodium falciparum W2 by [3H]hypoxanthine incorporation assay2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1714201Antimalarial activity against Plasmodium falciparum 3D72016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
In Vivo and In Vitro Optimization of Screening Antimalarial Hits toward Lead Molecules for Preclinical Development.
AID1686001Antiplasmodial activity against drug resistant Plasmodium falciparum 7G8 by [3H]hypoxanthine incorporation assay2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1685961Antiplasmodial activity against Plasmodium yoelli liver stage forms2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1685963Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 infected in human red blood cells assessed as growth inhibition by SYBR Green fluorescence assay2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1714195Antimalarial activity against Plasmodium berghei ookinete form2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
In Vivo and In Vitro Optimization of Screening Antimalarial Hits toward Lead Molecules for Preclinical Development.
AID1685958Antiplasmodial activity against drug resistant Plasmodium falciparum K1 by [3H]hypoxanthine incorporation assay2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1685993Half-life in Sprague-Dawley rat at 1 mg/kg, iv administered as bolus dose by UPLC-MS/MS analysis2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1714187Antimalarial activity against Plasmodium berghei infected in orally dosed mouse assessed as reduction in parasitemia2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
In Vivo and In Vitro Optimization of Screening Antimalarial Hits toward Lead Molecules for Preclinical Development.
AID1685981Antiplasmodial activity against Plasmodium berghei ANKA infected in NMRI mouse assessed as survival days at 30 mg/kg, po QD for 4 days2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1685970Protein binding in CD1 mouse plasma measured after 5 hr by UPLC-MS/MS analysis based equilibrium dialysis method2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1685988Antiplasmodial activity against Plasmodium berghei ANKA infected in NMRI mouse assessed as reduction in parasitemia at 1 mg/kg, po QD for 4 days2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1685971Inhibition of human ERG by IonWorks patch-clamp electrophysiology method2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1714186Antimalarial activity against Plasmodium berghei infected in mouse assessed as reduction in parasitemia at 1 mg/kg, po dosed 4 times2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
In Vivo and In Vitro Optimization of Screening Antimalarial Hits toward Lead Molecules for Preclinical Development.
AID1685985Antiplasmodial activity against Plasmodium berghei ANKA infected in NMRI mouse assessed as cure rate at 10 mg/kg, po QD for 4 days2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1439850Selectivity index, ratio of IC50 for rat L6 cells to IC50 for erythrocytic stage of chloroquine-sensitive Plasmodium falciparum NF542017Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
New derivatives of quinoline-4-carboxylic acid with antiplasmodial activity.
AID1714196Antimalarial activity against Plasmodium falciparum late stage (IV-V) gametocytes2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
In Vivo and In Vitro Optimization of Screening Antimalarial Hits toward Lead Molecules for Preclinical Development.
AID1685984Antiplasmodial activity against Plasmodium berghei ANKA infected in NMRI mouse assessed as survival days at 10 mg/kg, po QD for 4 days2016Journal of medicinal chemistry, 11-10, Volume: 59, Issue:21
Discovery of a Quinoline-4-carboxamide Derivative with a Novel Mechanism of Action, Multistage Antimalarial Activity, and Potent in Vivo Efficacy.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347159Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (55.56)24.3611
2020's4 (44.44)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.88

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.88 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.55 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.88)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (88.89%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
phenytoin
[no description available]		3.5110imidazolidine-2,4-dioneanticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent
beta-naphthoflavone
beta-Naphthoflavone: A polyaromatic hydrocarbon inducer of P4501A1 and P4501A2 cytochromes. (Proc Soc Exp Biol Med 1994 Dec:207(3):302-308). beta-naphthoflavone : An extended flavonoid resulting from the formal fusion of a benzene ring with the f side of flavone.		3.5110extended flavonoid;
naphtho-gamma-pyrone;
organic heterotricyclic compound		aryl hydrocarbon receptor agonist
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		2.1510aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
beta-lapachone
beta-lapachone: antineoplastic inhibitor of reverse transcriptase, DNA topoisomerase, and DNA polymerase. beta-lapachone : A benzochromenone that is 3,4-dihydro-2H-benzo[h]chromene-5,6-dione substituted by geminal methyl groups at position 2. Isolated from Tabebuia avellanedae, it exhibits antineoplastic and anti-inflammatory activities.		3.5110benzochromenone;
orthoquinones		anti-inflammatory agent;
antineoplastic agent;
plant metabolite
mebendazole
Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.		3.5110aromatic ketone;
benzimidazoles;
carbamate ester		antinematodal drug;
microtubule-destabilising agent;
tubulin modulator
thalidomide
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.		3.5110phthalimides;
piperidones
podophyllotoxin
Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.		2.1510furonaphthodioxole;
lignan;
organic heterotetracyclic compound		antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator
artemisinin
(+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.		2.5420organic peroxide;
sesquiterpene lactone		antimalarial;
plant metabolite
3-heptyl-4-hydroxy-7-methoxy-2-methylquinoline
3-heptyl-4-hydroxy-7-methoxy-2-methylquinoline: structure given in first source		3.5110
pyronaridine
[no description available]		2.5820aminoquinoline
tafenoquine
tafenoquine : A racemate comprising equimolar amounts of (R)- and (S)-tafenoquine.. N(4)-{2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine : An aminoquinoline that is 8-aminoquinoline which is substituted by methoxy groups at positions 2 and 6, a methyl group at position 4, and a m-(trifluoromethyl)phenoxy group at position 5, and in which the amino substituent at position 8 is itself substituted by a 5-aminopentan-2-yl group.		2.1310(trifluoromethyl)benzenes;
aminoquinoline;
aromatic ether;
primary amino compound;
secondary amino compound
peptide elongation factor 2
Peptide Elongation Factor 2: Peptide Elongation Factor 2 catalyzes the translocation of peptidyl-tRNA from the A site to the P site of eukaryotic ribosomes by a process linked to the hydrolysis of GTP to GDP.		2.5720
etravirine
[no description available]		3.5110aminopyrimidine;
aromatic ether;
dinitrile;
organobromine compound		antiviral agent;
HIV-1 reverse transcriptase inhibitor
linezolid
[no description available]		3.5110acetamides;
morpholines;
organofluorine compound;
oxazolidinone		antibacterial drug;
protein synthesis inhibitor
antofine
antofine: structure in first source. (-)-antofine : An organic heteropentacyclic compound that is (13aR)-9,11,12,13,13a,14-hexahydrodibenzo[f,h]pyrrolo[1,2-b]isoquinoline substituted at positions 2, 3 and 6 by methoxy groups. It is an alkaloid produced by relatives of the milkweed family and exhibits antiviral, anti-inflammatory, antiadipogenic and antitumorigenic activities.		3.5110alkaloid antibiotic;
alkaloid;
aromatic ether;
organic heteropentacyclic compound		angiogenesis inhibitor;
anti-inflammatory agent;
antimicrobial agent;
antineoplastic agent;
antiviral agent;
phytotoxin;
plant metabolite
ac 55649
4'-octyl-4-biphenylcarboxylic acid: an RAR beta2 agonist; structure in first source		3.5110biphenyls;
carboxybiphenyl
diosmin
[no description available]		3.5110dihydroxyflavanone;
disaccharide derivative;
glycosyloxyflavone;
monomethoxyflavone;
rutinoside		anti-inflammatory agent;
antioxidant
oridonin
[no description available]		3.5110cyclic hemiketal;
enone;
ent-kaurane diterpenoid;
organic heteropentacyclic compound;
secondary alcohol		angiogenesis inhibitor;
anti-asthmatic agent;
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
plant metabolite
rilpivirine
[no description available]		3.5110aminopyrimidine;
nitrile		EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor
a 286982
A 286982: inhibits the interaction between leukocyte function-associated antigen-1 and intracellular adhesion molecule-1; structure in first source		3.5110
SIS3 free base
SIS3 free base : An enamide resulting from the formal condensation of the amino group of 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline with the carboxy group of (2E)-3-(1-methyl-2-phenyl-1H-pyrrolo[2,3-b]pyridin-3-yl)acrylic acid.		3.5110aromatic ether;
enamide;
isoquinolines;
monocarboxylic acid amide;
pyrrolopyridine;
tertiary carboxamide		Smad3 inhibitor
bms-585248
[no description available]		3.5110
tedizolid
DA 7157: an anti-infective agent; structure in first source. tedizolid : A member of the class of pyridines that is pyridine which is substituted by a 2-methyl-2H-tetrazol-5-yl group at position 2 and by a 2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl group at position 5. It is used as its phosphate pro-drug used for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and methicillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis.		3.5110carbamate ester;
organofluorine compound;
oxazolidinone;
primary alcohol;
pyridines;
tetrazoles		antimicrobial agent;
drug metabolite;
protein synthesis inhibitor
bms-626529
[no description available]		3.5110
bms-663068
fostemsavir: an HIV-1 attachment inhibitor; structure in first source		3.5110
tedizolid phosphate
tedizolid phosphate: a prodrug of DA-7157; structure in first source. tedizolid phosphate : A phosphate monoester resulting from the formal condensation of equimolar amounts of phosphoric acid with the hydroxy group of tedizolid . It is a prodrug of tedizolid, used for the treatment of acute bacterial skin infections caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and methicillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis.		3.5110carbamate ester;
organofluorine compound;
oxazolidinone;
phosphate monoester;
pyridines;
tetrazoles		antimicrobial agent;
prodrug;
protein synthesis inhibitor
psi 697
2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo(H)quinoline-4-carboxylic acid: inhibitor of P selectin that decreases vein wall injury in a rat stenosis model of venous thrombosis		3.5110
amg 517
[no description available]		3.5110
azd1283
[no description available]		3.5110
(3R)-4-[2-(1H-indol-4-yl)-6-(1-methylsulfonylcyclopropyl)-4-pyrimidinyl]-3-methylmorpholine
[no description available]		3.5110indoles
7-chloro-3-methyl-2-(4-(4-(trifluoromethoxy)benzyl)phenyl)quinolin-4(1h)-one
7-chloro-3-methyl-2-(4-(4-(trifluoromethoxy)benzyl)phenyl)quinolin-4(1H)-one: an antimalarial; structure in first source		3.5110
gs-9973
[no description available]		3.5110
ConditionIndicatedRelationship StrengthStudiesTrials
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.5820
Infections, Plasmodium
[description not available]		02.8130
Malaria
A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia.		02.8130
Congenital Zika Syndrome
[description not available]		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510
Plasmodium falciparum Malaria
[description not available]		02.2510
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		02.2510